Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 13 entries
Sorted by: Best Match Show Resources per page
Physiologic Source of Intestinal FDG Uptake. Effect of Atropine and Sincalide.

Clinical positron imaging : official journal of the Institute for Clinical P.E.T

Jadvar H, Schambye RB, Segall GM.
PMID: 14516615
Clin Positron Imaging. 1999 Nov;2(6):318. doi: 10.1016/s1095-0397(99)00078-3.

No abstract available.

Cite
Jadvar H, Schambye RB, Segall GM. Physiologic Source of Intestinal FDG Uptake. Effect of Atropine and Sincalide. Clin Positron Imaging. 1999;2(6):318doi: 10.1016/s1095-0397(99)00078-3.
Jadvar, H., Schambye, R. B., & Segall, G. M. (1999). Physiologic Source of Intestinal FDG Uptake. Effect of Atropine and Sincalide. Clinical positron imaging : official journal of the Institute for Clinical P.E.T, 2(6), 318. https://doi.org/10.1016/s1095-0397(99)00078-3
Jadvar, H, et al. "Physiologic Source of Intestinal FDG Uptake. Effect of Atropine and Sincalide." Clinical positron imaging : official journal of the Institute for Clinical P.E.T vol. 2,6 (1999): 318. doi: https://doi.org/10.1016/s1095-0397(99)00078-3
Jadvar H, Schambye RB, Segall GM. Physiologic Source of Intestinal FDG Uptake. Effect of Atropine and Sincalide. Clin Positron Imaging. 1999 Nov;2(6):318. doi: 10.1016/s1095-0397(99)00078-3. PMID: 14516615.
Copy Download .nbib Format: NLM
Hepatobiliary scintigraphy in 2014.

Journal of nuclear medicine technology

Ziessman HA.
PMID: 25472513
J Nucl Med Technol. 2014 Dec;42(4):249-59. doi: 10.2967/jnumed.113.131490.

Cholescintigraphy with (99m)Tc-hepatobiliary radiopharmaceuticals has been an important, clinically useful diagnostic imaging study for almost 4 decades. It continues to be in much clinical demand; however, the indications, methodology, and interpretative criteria have evolved over the years. This review...

Cite
Ziessman HA. Hepatobiliary scintigraphy in 2014. J Nucl Med Technol. 2014;42(4):249-59doi: 10.2967/jnumed.113.131490.
Ziessman, H. A. (2014). Hepatobiliary scintigraphy in 2014. Journal of nuclear medicine technology, 42(4), 249-59. https://doi.org/10.2967/jnumed.113.131490
Ziessman, Harvey A. "Hepatobiliary scintigraphy in 2014." Journal of nuclear medicine technology vol. 42,4 (2014): 249-59. doi: https://doi.org/10.2967/jnumed.113.131490
Ziessman HA. Hepatobiliary scintigraphy in 2014. J Nucl Med Technol. 2014 Dec;42(4):249-59. doi: 10.2967/jnumed.113.131490. PMID: 25472513.
Copy Download .nbib Format: NLM
Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study.

The Lancet. Rheumatology

Biran N, Ip A, Ahn J, Go RC, Wang S, Mathura S, Sinclaire BA, Bednarz U, Marafelias M, Hansen E, Siegel DS, Goy AH, Pecora AL, Sawczuk IS, Koniaris LS, Simwenyi M, Varga DW, Tank LK, Stein AA, Allusson V, Lin GS, Oser WF, Tuma RA, Reichman J, Brusco L, Carpenter KL, Costanzo EJ, Vivona V, Goldberg SL.
PMID: 32838323
Lancet Rheumatol. 2020 Oct;2(10):e603-e612. doi: 10.1016/S2665-9913(20)30277-0. Epub 2020 Aug 14.

BACKGROUND: Tocilizumab, a monoclonal antibody directed against the interleukin-6 receptor, has been proposed to mitigate the cytokine storm syndrome associated with severe COVID-19. We aimed to investigate the association between tocilizumab exposure and hospital-related mortality among patients requiring intensive...

Cite
Biran N, Ip A, Ahn J, et al. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. Lancet Rheumatol. 2020;2(10):e603-e612doi: 10.1016/S2665-9913(20)30277-0.
Biran, N., Ip, A., Ahn, J., Go, R. C., Wang, S., Mathura, S., Sinclaire, B. A., Bednarz, U., Marafelias, M., Hansen, E., Siegel, D. S., Goy, A. H., Pecora, A. L., Sawczuk, I. S., Koniaris, L. S., Simwenyi, M., Varga, D. W., Tank, L. K., Stein, A. A., Allusson, V., Lin, G. S., Oser, W. F., Tuma, R. A., Reichman, J., Brusco, L., Carpenter, K. L., Costanzo, E. J., Vivona, V., & Goldberg, S. L. (2020). Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. The Lancet. Rheumatology, 2(10), e603-e612. https://doi.org/10.1016/S2665-9913(20)30277-0
Biran, Noa, et al. "Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study." The Lancet. Rheumatology vol. 2,10 (2020): e603-e612. doi: https://doi.org/10.1016/S2665-9913(20)30277-0
Biran N, Ip A, Ahn J, Go RC, Wang S, Mathura S, Sinclaire BA, Bednarz U, Marafelias M, Hansen E, Siegel DS, Goy AH, Pecora AL, Sawczuk IS, Koniaris LS, Simwenyi M, Varga DW, Tank LK, Stein AA, Allusson V, Lin GS, Oser WF, Tuma RA, Reichman J, Brusco L, Carpenter KL, Costanzo EJ, Vivona V, Goldberg SL. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. Lancet Rheumatol. 2020 Oct;2(10):e603-e612. doi: 10.1016/S2665-9913(20)30277-0. Epub 2020 Aug 14. PMID: 32838323; PMCID: PMC7428303.
Copy Download .nbib Format: NLM
Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies.

European journal of cancer (Oxford, England : 1990)

Geoerger B, Morland B, Jiménez I, Frappaz D, Pearson ADJ, Vassal G, Maeda P, Kincaide J, Mueller U, Schlief S, Teufel M, Ploeger BA, Cleton A, Agostinho AC, Marshall LV.
PMID: 34157616
Eur J Cancer. 2021 Aug;153:142-152. doi: 10.1016/j.ejca.2021.05.023. Epub 2021 Jun 20.

BACKGROUND: This phase 1 study evaluated safety, pharmacokinetics (PK), maximum tolerated dose (MTD), and antitumour activity of regorafenib in paediatric patients with solid tumours.PATIENTS AND METHODS: Patients (aged 6 months to

Cite
Geoerger B, Morland B, Jiménez I, et al. Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies. Eur J Cancer. 2021;153:142-152doi: 10.1016/j.ejca.2021.05.023.
Geoerger, B., Morland, B., Jiménez, I., Frappaz, D., Pearson, A. D. J., Vassal, G., Maeda, P., Kincaide, J., Mueller, U., Schlief, S., Teufel, M., Ploeger, B. A., Cleton, A., Agostinho, A. C., & Marshall, L. V. (2021). Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies. European journal of cancer (Oxford, England : 1990), 153142-152. https://doi.org/10.1016/j.ejca.2021.05.023
Geoerger, Birgit, et al. "Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies." European journal of cancer (Oxford, England : 1990) vol. 153 (2021): 142-152. doi: https://doi.org/10.1016/j.ejca.2021.05.023
Geoerger B, Morland B, Jiménez I, Frappaz D, Pearson ADJ, Vassal G, Maeda P, Kincaide J, Mueller U, Schlief S, Teufel M, Ploeger BA, Cleton A, Agostinho AC, Marshall LV. Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies. Eur J Cancer. 2021 Aug;153:142-152. doi: 10.1016/j.ejca.2021.05.023. Epub 2021 Jun 20. PMID: 34157616.
Copy Download .nbib Format: NLM
Immunosuppression in Lung Transplantation.

Handbook of experimental pharmacology

Nelson J, Kincaide E, Schulte J, Hall R, Levine DJ.
PMID: 34796380
Handb Exp Pharmacol. 2021 Nov 19; doi: 10.1007/164_2021_548. Epub 2021 Nov 19.

Immunosuppression in lung transplantation is an area devoid of robust clinical data. This chapter will review the history of immunosuppression in lung transplantation. Additionally, it will evaluate the three classes of induction, maintenance, and rescue immunosuppression in detail. Induction...

Cite
Nelson J, Kincaide E, Schulte J, et al. Immunosuppression in Lung Transplantation. Handb Exp Pharmacol. 2021;doi: 10.1007/164_2021_548.
Nelson, J., Kincaide, E., Schulte, J., Hall, R., & Levine, D. J. (2021). Immunosuppression in Lung Transplantation. Handbook of experimental pharmacology, . https://doi.org/10.1007/164_2021_548
Nelson, Joelle, et al. "Immunosuppression in Lung Transplantation." Handbook of experimental pharmacology vol. (2021). doi: https://doi.org/10.1007/164_2021_548
Nelson J, Kincaide E, Schulte J, Hall R, Levine DJ. Immunosuppression in Lung Transplantation. Handb Exp Pharmacol. 2021 Nov 19; doi: 10.1007/164_2021_548. Epub 2021 Nov 19. PMID: 34796380.
Copy Download .nbib Format: NLM
Sincalide-Stimulated Cholescintigraphy: A Retrospective Study and Proposal of a Modified Workflow.

Clinical nuclear medicine

Vasireddi A, Nguyen NC.
PMID: 34874343
Clin Nucl Med. 2022 Jan 01;47(1):1-6. doi: 10.1097/RLU.0000000000003959.

PURPOSE: Current guidelines for sincalide-stimulated cholescintigraphy (SSC) call for a 60-minute sincalide infusion, and a gallbladder ejection fraction (GBEF) ≥38% is considered normal. In this retrospective study, we hypothesize that most patients reach a normal GBEF by 30 minutes.METHODS:...

Cite
Vasireddi A, Nguyen NC. Sincalide-Stimulated Cholescintigraphy: A Retrospective Study and Proposal of a Modified Workflow. Clin Nucl Med. 2022;47(1):1-6doi: 10.1097/RLU.0000000000003959.
Vasireddi, A., & Nguyen, N. C. (2022). Sincalide-Stimulated Cholescintigraphy: A Retrospective Study and Proposal of a Modified Workflow. Clinical nuclear medicine, 47(1), 1-6. https://doi.org/10.1097/RLU.0000000000003959
Vasireddi, Anil, and Nguyen, Nghi C. "Sincalide-Stimulated Cholescintigraphy: A Retrospective Study and Proposal of a Modified Workflow." Clinical nuclear medicine vol. 47,1 (2022): 1-6. doi: https://doi.org/10.1097/RLU.0000000000003959
Vasireddi A, Nguyen NC. Sincalide-Stimulated Cholescintigraphy: A Retrospective Study and Proposal of a Modified Workflow. Clin Nucl Med. 2022 Jan 01;47(1):1-6. doi: 10.1097/RLU.0000000000003959. PMID: 34874343.
Copy Download .nbib Format: NLM
Historical and Continued Colonial Impacts on Heart Health of Indigenous Peoples in Canada: What's Reconciliation Got to Do With It?.

CJC open

Schultz A, Nguyen T, Sinclaire M, Fransoo R, McGibbon E.
PMID: 34993444
CJC Open. 2021 Sep 24;3(12):S149-S164. doi: 10.1016/j.cjco.2021.09.010. eCollection 2021 Dec.

Colonization and enforced genocidal strategies have collectively fractured and changed Indigenous people by attempting to erase and dismiss their voices and knowledge. Nearly a decade ago, we were reminded by Dr Ku Young of the cardiovascular health disparities, in...

Cite
Schultz A, Nguyen T, Sinclaire M, et al. Historical and Continued Colonial Impacts on Heart Health of Indigenous Peoples in Canada: What's Reconciliation Got to Do With It?. CJC Open. 2021;3(12):S149-S164doi: 10.1016/j.cjco.2021.09.010.
Schultz, A., Nguyen, T., Sinclaire, M., Fransoo, R., & McGibbon, E. (2021). Historical and Continued Colonial Impacts on Heart Health of Indigenous Peoples in Canada: What's Reconciliation Got to Do With It?. CJC open, 3(12), S149-S164. https://doi.org/10.1016/j.cjco.2021.09.010
Schultz, Annette, et al. "Historical and Continued Colonial Impacts on Heart Health of Indigenous Peoples in Canada: What's Reconciliation Got to Do With It?." CJC open vol. 3,12 (2021): S149-S164. doi: https://doi.org/10.1016/j.cjco.2021.09.010
Schultz A, Nguyen T, Sinclaire M, Fransoo R, McGibbon E. Historical and Continued Colonial Impacts on Heart Health of Indigenous Peoples in Canada: What's Reconciliation Got to Do With It?. CJC Open. 2021 Sep 24;3(12):S149-S164. doi: 10.1016/j.cjco.2021.09.010. eCollection 2021 Dec. PMID: 34993444; PMCID: PMC8712585.
Copy Download .nbib Format: NLM
Historical and Continued Colonial Impacts on Heart Health of Indigenous Peoples in Canada: What's Reconciliation Got to Do With It?.

CJC open

Schultz A, Nguyen T, Sinclaire M, Fransoo R, McGibbon E.
PMID: 34993444
CJC Open. 2021 Sep 24;3(12):S149-S164. doi: 10.1016/j.cjco.2021.09.010. eCollection 2021 Dec.

Colonization and enforced genocidal strategies have collectively fractured and changed Indigenous people by attempting to erase and dismiss their voices and knowledge. Nearly a decade ago, we were reminded by Dr Ku Young of the cardiovascular health disparities, in...

Cite
Schultz A, Nguyen T, Sinclaire M, et al. Historical and Continued Colonial Impacts on Heart Health of Indigenous Peoples in Canada: What's Reconciliation Got to Do With It?. CJC Open. 2021;3(12):S149-S164doi: 10.1016/j.cjco.2021.09.010.
Schultz, A., Nguyen, T., Sinclaire, M., Fransoo, R., & McGibbon, E. (2021). Historical and Continued Colonial Impacts on Heart Health of Indigenous Peoples in Canada: What's Reconciliation Got to Do With It?. CJC open, 3(12), S149-S164. https://doi.org/10.1016/j.cjco.2021.09.010
Schultz, Annette, et al. "Historical and Continued Colonial Impacts on Heart Health of Indigenous Peoples in Canada: What's Reconciliation Got to Do With It?." CJC open vol. 3,12 (2021): S149-S164. doi: https://doi.org/10.1016/j.cjco.2021.09.010
Schultz A, Nguyen T, Sinclaire M, Fransoo R, McGibbon E. Historical and Continued Colonial Impacts on Heart Health of Indigenous Peoples in Canada: What's Reconciliation Got to Do With It?. CJC Open. 2021 Sep 24;3(12):S149-S164. doi: 10.1016/j.cjco.2021.09.010. eCollection 2021 Dec. PMID: 34993444; PMCID: PMC8712585.
Copy Download .nbib Format: NLM
Chitotriosidase deficiency: a mutation update in an african population.

JIMD reports

Arndt S, Hobbs A, Sinclaire I, Lane AB.
PMID: 23430794
JIMD Rep. 2013;10:11-6. doi: 10.1007/8904_2012_193. Epub 2012 Dec 29.

Human plasma chitotriosidase activity is a commonly used diagnostic and therapeutic biomarker for non-neuronopathic Gaucher disease. Chitotriosidase deficiency is common in non-African populations and is primarily caused by a 24 bp duplication in the encoding gene (CHIT1). Allele frequencies...

Cite
Arndt S, Hobbs A, Sinclaire I, et al. Chitotriosidase deficiency: a mutation update in an african population. JIMD Rep. 2012;10:11-6doi: 10.1007/8904_2012_193.
Arndt, S., Hobbs, A., Sinclaire, I., & Lane, A. B. (2013). Chitotriosidase deficiency: a mutation update in an african population. JIMD reports, 1011-6. https://doi.org/10.1007/8904_2012_193
Arndt, Silke, et al. "Chitotriosidase deficiency: a mutation update in an african population." JIMD reports vol. 10 (2013): 11-6. doi: https://doi.org/10.1007/8904_2012_193
Arndt S, Hobbs A, Sinclaire I, Lane AB. Chitotriosidase deficiency: a mutation update in an african population. JIMD Rep. 2013;10:11-6. doi: 10.1007/8904_2012_193. Epub 2012 Dec 29. PMID: 23430794; PMCID: PMC3755570.
Copy Download .nbib Format: NLM
Rapid Sequence Intubation from the Patient's Perspective.

The western journal of emergency medicine

Kimball D, Kincaide RC, Ives C, Henderson S.
PMID: 22224118
West J Emerg Med. 2011 Nov;12(4):365-7. doi: 10.5811/westjem.2010.11.1922.

INTRODUCTION: This study assesses the efficacy of the rapid sequence intubation (RSI) protocol in preventing patient recollection of resuscitative events and patient discomfort during intubation, as subjectively determined by the patient.METHODS: This was a prospective study of all patients...

Cite
Kimball D, Kincaide RC, Ives C, et al. Rapid Sequence Intubation from the Patient's Perspective. West J Emerg Med. 2011;12(4):365-7doi: 10.5811/westjem.2010.11.1922.
Kimball, D., Kincaide, R. C., Ives, C., & Henderson, S. (2011). Rapid Sequence Intubation from the Patient's Perspective. The western journal of emergency medicine, 12(4), 365-7. https://doi.org/10.5811/westjem.2010.11.1922
Kimball, Deborah, et al. "Rapid Sequence Intubation from the Patient's Perspective." The western journal of emergency medicine vol. 12,4 (2011): 365-7. doi: https://doi.org/10.5811/westjem.2010.11.1922
Kimball D, Kincaide RC, Ives C, Henderson S. Rapid Sequence Intubation from the Patient's Perspective. West J Emerg Med. 2011 Nov;12(4):365-7. doi: 10.5811/westjem.2010.11.1922. PMID: 22224118; PMCID: PMC3236173.
Copy Download .nbib Format: NLM
The role of (99m)technetium-labelled hepato imino diacetic acid (HIDA) scan in the management of biliary pain.

HPB : the official journal of the International Hepato Pancreato Biliary Association

Riyad K, Chalmers CR, Aldouri A, Fraser S, Menon K, Robinson PJ, Toogood GJ.
PMID: 18333226
HPB (Oxford). 2007;9(3):219-24. doi: 10.1080/13651820701223022.

OBJECTIVE: To assess the outcome of laparoscopic cholecystectomy on the basis of an abnormal provocative (99m)technetium-labelled hepato imino diacetic acid (HIDA) scan for patients with typical biliary pain and normal trans-abdominal ultrasound (TUS) scan.PATIENTS AND METHODS: Prospective data were...

Cite
Riyad K, Chalmers CR, Aldouri A, et al. The role of (99m)technetium-labelled hepato imino diacetic acid (HIDA) scan in the management of biliary pain. HPB (Oxford). 2007;9(3):219-24doi: 10.1080/13651820701223022.
Riyad, K., Chalmers, C. R., Aldouri, A., Fraser, S., Menon, K., Robinson, P. J., & Toogood, G. J. (2007). The role of (99m)technetium-labelled hepato imino diacetic acid (HIDA) scan in the management of biliary pain. HPB : the official journal of the International Hepato Pancreato Biliary Association, 9(3), 219-24. https://doi.org/10.1080/13651820701223022
Riyad, K, et al. "The role of (99m)technetium-labelled hepato imino diacetic acid (HIDA) scan in the management of biliary pain." HPB : the official journal of the International Hepato Pancreato Biliary Association vol. 9,3 (2007): 219-24. doi: https://doi.org/10.1080/13651820701223022
Riyad K, Chalmers CR, Aldouri A, Fraser S, Menon K, Robinson PJ, Toogood GJ. The role of (99m)technetium-labelled hepato imino diacetic acid (HIDA) scan in the management of biliary pain. HPB (Oxford). 2007;9(3):219-24. doi: 10.1080/13651820701223022. PMID: 18333226; PMCID: PMC2063605.
Copy Download .nbib Format: NLM
Screening of FDA Approved Drugs Against SARS-CoV-2 Main Protease: Coronavirus Disease.

International journal of peptide research and therapeutics

Balakrishnan V, Lakshminarayanan K.
PMID: 33013255
Int J Pept Res Ther. 2020 Sep 28;1-8. doi: 10.1007/s10989-020-10115-6. Epub 2020 Sep 28.

At the end of December 2019, a new strain of coronavirus was identified in the Wuhan city of Hubei province in China. Within a shorter period of time, an unprecedented outbreak of this strain was witnessed over the entire...

Cite
Balakrishnan V, Lakshminarayanan K. Screening of FDA Approved Drugs Against SARS-CoV-2 Main Protease: Coronavirus Disease. Int J Pept Res Ther. 2020;1-8doi: 10.1007/s10989-020-10115-6.
Balakrishnan, V., & Lakshminarayanan, K. (2020). Screening of FDA Approved Drugs Against SARS-CoV-2 Main Protease: Coronavirus Disease. International journal of peptide research and therapeutics, 1-8. https://doi.org/10.1007/s10989-020-10115-6
Balakrishnan, Vijayakumar, and Lakshminarayanan, Karthik. "Screening of FDA Approved Drugs Against SARS-CoV-2 Main Protease: Coronavirus Disease." International journal of peptide research and therapeutics vol. (2020): 1-8. doi: https://doi.org/10.1007/s10989-020-10115-6
Balakrishnan V, Lakshminarayanan K. Screening of FDA Approved Drugs Against SARS-CoV-2 Main Protease: Coronavirus Disease. Int J Pept Res Ther. 2020 Sep 28;1-8. doi: 10.1007/s10989-020-10115-6. Epub 2020 Sep 28. PMID: 33013255; PMCID: PMC7521772.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 13 entries